BioCentury
ARTICLE | Company News

Almirall, Aslan deal

January 18, 2016 8:00 AM UTC

Aslan and Almirall expanded a 2012 deal to grant Aslan exclusive, worldwide rights to develop and commercialize ASLAN003 ( LAS186323) for all non-topical and non-dermatological indications, including cancer. The small molecule oral dihydroorotate dehydrogenase (DHODH) inhibitor has been studied in preclinical cancer models and Aslan plans to pursue several cancer indications as monotherapy and in combination with other compounds. This year, Aslan plans to start Phase I testing. ...